Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NGM120
- Development stage
- Phase 2
- Lead developer
- NGM Biopharmaceuticals
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Vaccines & Immunotherapeutics, Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
NGM120 is a long-acting, humanized monoclonal antibody that targets and blocks the glial-cell-derived neurotrophic factor (GDNF) family receptor alpha-like (GFRAL). By binding to GFRAL, it inhibits the activity of growth differentiation factor 15 (GDF15), a hormone implicated in nausea and vomiting during pregnancy as well as cancer-associated cachexia. The drug is being developed primarily for hyperemesis gravidarum—a severe form of nausea and vomiting in pregnancy—and has also been studied in advanced solid tumors and various cancers. Developed by NGM Biopharmaceuticals, Inc., it is currently under investigation in Phase 2 clinical trials for hyperemesis gravidarum[1][2][4][5][6][8].
- Other names
- anti-GFRAL monoclonal antibody NGM120
02
Targets
GFRAL (Glial-derived neurotrophic factor family receptor alpha-like/ret receptor complex)
Beyond the preview
Go deeper on NGM120.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NGM120.